Company Overview and News

 
Almaden Completes Dismantling of the Rock Creek Mill in Preparation for Shipping to Ixtaca and Provides Feasibility Update

2018-10-04 globenewswire
VANCOUVER, British Columbia, Oct. 04, 2018 (GLOBE NEWSWIRE) -- Almaden Minerals Ltd. (“Almaden” or “the Company”; TSX: AMM; NYSE American: AAU) is pleased to report that dismantling of the Rock Creek mill was completed in August, and the mill components have since been cleaned, crated and packed to ensure safe storage near the port of Nome, Alaska. The Rock Creek mill is now fully owned by Almaden and ready for anticipated shipping to Mexico in 2019.
AMZ AAU AMM AXDDF

1
Almaden Minerals: Low Price, Attractive Project, Permitting Issues

2018-08-03 seekingalpha - 1
A feasibility study incorporating the sensor-based ore sorting should be completed by the end of 2018.
AAU AMM

 
Almaden Achieves 39% Gold And 47% Silver Mill Feed Grade Increase From Bulk Ore Sort Tests for Ixtaca

2018-07-16 globenewswire
VANCOUVER, British Columbia, July 16, 2018 (GLOBE NEWSWIRE) -- Almaden Minerals Ltd. (“Almaden” or “the Company”) (TSX:AMM) (NYSE American:AAU) is pleased to announce that it has achieved positive results from ore sorting trials carried out on ore samples from the Ixtaca gold-silver project located in Puebla State, Mexico. The ore sorting tests were carried out on a commercial XRT sorter using a bulk sample from the limestone host rock in the Ixtaca Main zone.
AMZ AAU AMM AXDDF

5
Almaden Announces Results of Annual General Meeting

2018-06-28 globenewswire
VANCOUVER, British Columbia, June 28, 2018 (GLOBE NEWSWIRE) -- Almaden Minerals Ltd. (“Almaden" or the "Company") (TSX:AMM) (NYSE American:AAU) is pleased to provide the results of its Annual General Meeting held on June 28, 2018.
AMZ AAU AMM AXDDF

5
Almaden Closes Oversubscribed $9.4 Million Non-Brokered Private Placement

2018-06-07 globenewswire
VANCOUVER, British Columbia, June 07, 2018 (GLOBE NEWSWIRE) -- Almaden Minerals Ltd. (“Almaden” or “the Company”) (TSX:AMM) (NYSE American:AAU) is pleased to announce that it has closed its previously announced non-brokered private placement with the issuance of 9,440,000 units (“Units”) at $1.00 per Unit (the “Offering”). Each Unit consisted of one common share of the Company (a “Common Share”) and one-half of one non-transferable Common Share purchase warrant (each such whole Common Share purchase warrant, a “Warrant”).
AMZ AAU AMM AXDDF

6
Almaden Announces $7 Million Non-Brokered Private Placement

2018-05-11 globenewswire - 1
VANCOUVER, B.C., May 11, 2018 (GLOBE NEWSWIRE) -- Almaden Minerals Ltd. (“Almaden” or “the Company”) (TSX:AMM) (NYSE American:AAU) is pleased to announce a proposed non-brokered private placement financing (the "Offering") of up to 7,000,000 units (the “Units”) to raise up to $7,000,000 at a price of $1.00 per Unit.
AMZ AAU AMM AXDDF

6
Almadex Shareholders Approve Spinout Transaction; Almadex Updates Transaction Timing

2018-05-08 globenewswire - 1
VANCOUVER, British Columbia, May 08, 2018 (GLOBE NEWSWIRE) -- Almadex Minerals Limited (“Almadex” or the “Company”); (TSX-V:AMZ); (OTCQX:AXDDF) is pleased to announce that shareholders at its Special Meeting of shareholders held today in Vancouver have voted 99.97% in favour of a special resolution approving a statutory plan of arrangement (the “Plan of Arrangement”) under Section 288 of the Business Corporations Act (British Columbia) to spin-out Almadex’s early stage exploration projects, royalty interests, and certain other assets into 1154229 B.
AMZ AAU AMM AXDDF

5
Almadex Provides Update On Spin-Out Transaction and Newcrest Investment

2018-04-16 globenewswire
VANCOUVER, British Columbia, April 16, 2018 (GLOBE NEWSWIRE) -- Almadex Minerals Limited (“Almadex” or the “Company”) (TSX-V:AMZ) (OTCQX:AXDDF) announces that, further to its news release dated February 26, 2018, the Company has mailed and filed its Notice of Special Meeting of Shareholders (the “Meeting”) and the related Management Information Circular (the “Circular”) which describes, amongst other things, the proposed spin-out of Almadex’s early stage exploration projects, royalty interests and certain other assets, into a new public company (“Spinco”).
AMZ AAU AMM AXDDF

5
Almaden Files Form 20-F Documentation

2018-03-29 globenewswire
VANCOUVER, British Columbia, March 28, 2018 (GLOBE NEWSWIRE) -- Almaden Minerals Ltd. (“Almaden” or “the Company”) (TSX:AMM) (NYSE American:AAU) announces that its Form 20-F for the fiscal year ended December 31, 2017 has been filed with the U.S. Securities and Exchange Commission. The Form 20-F and the Company's audited consolidated financial statements for the years ended December 31, 2017 and 2016 are available on the Company's website at http://www.
AMZ AAU AMM AXDDF

5
Almadex Minerals Announces Closing of $5.6 Million Non-Brokered Private Placement

2018-03-28 globenewswire
VANCOUVER, B.C. , March 27, 2018 (GLOBE NEWSWIRE) -- Almadex Minerals Limited (“Almadex” or the “Company”) (TSX-V:AMZ) (OTCQB:AXDDF) is pleased to announce that it has closed its previously announced non-brokered private placement with the issuance of 4,000,000 units (“Units”) at $1.40 per Unit. Each Unit consists of one common share of the Company and one-half of one non-transferable common share purchase warrant (each such whole share purchase warrant, a “Warrant”).
AMZ AAU AMM AXDDF

5
Almaden Updates Feasibility Study at Ixtaca

2018-03-21 globenewswire
VANCOUVER, British Columbia, March 21, 2018 (GLOBE NEWSWIRE) -- Almaden Minerals Ltd. (“Almaden” or “the Company”) (NYSE American:AAU) (TSX:AMM) is pleased to update investors on the environmental and engineering work relating to the feasibility study (FS) at the Ixtaca gold-silver project located in Puebla State, Mexico.
AMZ AAU AMM AXDDF

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to TSX:AMM / Almaden Minerals Ltd. on message board site Silicon Investor.

SI Spammer Hall of Fame SI Spammer Hall of Fame SI Spammer Hall of Fame SI Grammar and Spelling Lab SI Grammar and Spelling Lab SI Grammar and Spelling Lab
[email protected] u0026 TRUTHSEEKER Expose Crims u0026 Scammers!!! [email protected] u0026 TRUTHSEEKER Expose Crims u0026 Scammers!!! [email protected] u0026 TRUTHSEEKER Expose Crims u0026 Scammers!!! Indications -- Psoriasis/Chronic Inflammation Indications -- Psoriasis/Chronic Inflammation Indications -- Psoriasis/Chronic Inflammation
JAMN... JAMMIN JAVA JAMN... JAMMIN JAVA JAMN... JAMMIN JAVA Indications -- Sepsis/Acute Inflammation Indications -- Sepsis/Acute Inflammation Indications -- Sepsis/Acute Inflammation
Mu Gamma Lambda Mu Gamma Lambda Mu Gamma Lambda Simple Programming Trickz Simple Programming Trickz Simple Programming Trickz
Gammon Lake Resources GAM-TSE Gammon Lake Resources GAM-TSE Gammon Lake Resources GAM-TSE Gammon Lake (GAM.TO) Gammon Lake (GAM.TO) Gammon Lake (GAM.TO)